

*Listing of the Claims*

This listing of claims will replace all prior versions, and listings of claims in the application.

1-70 (Canceled)

71.(Currently Amended) A composition for amplifying a target nucleic acid, said composition comprising said target nucleic acid; a first primer comprising a random sequence of nucleotides at its 3' end and a generic sequence 5' of the random nucleotides; a second primer comprising said generic sequence and lacking said random sequence; and a heat-stable DNA polymerase; wherein said target nucleic acid is fixed to a solid medium.

72. (Previously Presented) The composition of claim 71, wherein said first primer and said second primer are between about 5 and 100 nucleotides in length.

73. (Previously Presented) The composition of claim 71, wherein said random sequence comprises about 4 to about 9 nucleotides.

74. (Previously Presented) The composition of claim 73, wherein said random sequence comprises about 5 to about 8 nucleotides.

75. (Previously Presented) The composition of claim 71, wherein said generic sequence comprises about 10 to about 30 nucleotides.

76. (Previously Presented) The composition of claim 75, wherein said generic sequence comprises about 15 to about 25 nucleotides.

77. (Previously Presented) The composition of claim 71, wherein said random sequence and said generic sequence in said first primer are adjacent.

78. (Previously Presented) The composition of claim 71, wherein one or more nucleotides are inserted between said random sequence and said generic sequence in said first primer.

79. (Previously Presented) The composition of claim 71, wherein said first primer comprises additional nucleotides 5' of said generic sequence.

80. (Previously Presented) The composition of claim 71, wherein said random sequence of said first primer is A-T rich.

81. (Previously Presented) The composition of claim 71, wherein said random sequence of said first primer is G-C rich.

82. (Previously Presented) The composition of claim 71, wherein said heat-stable polymerase has 5' to 3' exonuclease activity.

83. (Previously Presented) The composition of claim 71, wherein said heat-stable polymerase has primer displacement activity.

84. (Previously Presented) The composition of claim 82, wherein said heat-stable polymerase is Taq polymerase.

85. (Previously Presented) The composition of claim 71, wherein said heat-stable polymerase is selected from the group consisting of Pfu DNA polymerase, Vent DNA

polymerase, Tub DNA polymerase, Tfl DNA polymerase, Tli DNA polymerase and Tth DNA polymerase.

86. (Previously Presented) The composition of claim 71, wherein one or both of said primers comprise a label selected from the group consisting of a ligand, antibody and affinity label.

87. (Previously Presented) The composition of claim 71, wherein one or both of said primers comprise a label selected from the group consisting of a fluorescent label, radioactive label, mass label, chromophore, dye, electroluminescent label, chemiluminescent label and enzymatic label.

88. (Previously Presented) The composition of claim 71, wherein one or both of said primers comprises one or more restriction sites.

89. (Previously Presented) The composition of claim 71, further comprising one or more dNTPs.

90. (Previously Presented) The composition of claim 71, further comprising one or more buffer salts.

91. (Previously Presented) The composition of claim 71, further comprising a target nucleic acid.

92. (Previously Presented) The composition of claim 91, wherein said target nucleic acid is DNA.

93. (Previously Presented) The composition of claim 92, wherein said DNA is selected from the group consisting of genomic DNA, microdissected chromosome DNA, yeast artificial chromosome (YAC) DNA, P1 phage DNA or bacterial artificial chromosome (BAC) DNA.

94. (Previously Presented) The composition of claim 92, wherein said DNA is obtained from a tissue sample.

95. (Previously Presented) The composition of claim 92, wherein said DNA is human DNA.

96. (Previously Presented) The composition of claim 91, wherein said target nucleic acid is RNA or mRNA.